therapeutic action: improved emotional regulation

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US

mycolabadmin

Researchers are studying psilocybin, a compound from certain mushrooms, as a potential treatment for depression, anxiety, and addiction. The United States has significantly more clinical trials underway than the European Union, reflecting different regulatory approaches and funding levels. While US trials progress faster, EU trials emphasize safety and careful evaluation. Both regions show promising results when psilocybin is combined with professional psychological support in controlled settings.

Read More »

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity

mycolabadmin

This review examines how psilocybin, the active compound in certain mushrooms, may help treat depression and anxiety by reducing brain inflammation and promoting healthy neurotransmitter function. Both full doses under medical supervision and smaller ‘microdoses’ show promise for mental health conditions. The research suggests psilocybin works by calming the immune system’s inflammatory response while simultaneously supporting the brain’s natural healing and adaptation processes, offering a potential alternative treatment when standard medications don’t work.

Read More »

Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: An fMRI pilot study

mycolabadmin

This pilot study examined how psilocybin affects the brains of people with alcohol use disorder. Using brain imaging (fMRI), researchers found that psilocybin increased activity in brain regions associated with decision-making and emotional control while decreasing activity in regions linked to cravings. These findings suggest psilocybin may help people with alcohol addiction by enhancing their ability to regulate emotions and resist urges to drink.

Read More »

Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective

mycolabadmin

This scientific commentary examines how research on psychedelic-assisted therapy for eating disorders may be missing important aspects of how people actually experience the treatment. The authors argue that current study methods rely too heavily on questionnaires that don’t capture the full depth of what people experience during psychedelic sessions. They propose using phenomenological approaches—methods that deeply explore lived experience—to better understand which aspects of the psychedelic experience actually lead to recovery from eating disorders.

Read More »
Scroll to Top